ReCor Medical v. Medtronic Ardian: Renal Denervation DJ Action Dismissed
ReCor Medical filed a declaratory judgment action against Medtronic Ardian in the Eastern District of California, challenging US8845629B2 in connection with its Paradise Ultrasound Renal Denervation system. After 978 days of litigation, ReCor voluntarily dismissed the case without prejudice — leaving the patent dispute technically unresolved.
A DJ battle over ultrasound renal denervation ends without a verdict
ReCor Medical, Inc. initiated this declaratory judgment action on 13 January 2022 in the Eastern District of California, seeking a ruling on US8845629B2 — a patent held by Medtronic Ardian Luxembourg S.A.R.L. covering ultrasound-based renal denervation technology. The case centred on ReCor’s Paradise Ultrasound Renal Denervation system, a competing device in the catheter-based hypertension treatment space. Judge Kandis A. Westmore presided over the proceedings.
On 17 September 2024, after 978 days, ReCor Medical voluntarily dismissed the action without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). This procedural mechanism — available to a plaintiff before the defendant serves an answer or a motion for summary judgment — ends the case without any ruling on the merits. The ‘without prejudice’ designation means ReCor retains the theoretical right to re-file the declaratory judgment claim in the future, though strategic and commercial factors would govern any such decision.
The duration of nearly 2.7 years before voluntary dismissal is notable: it suggests the parties engaged in substantive pre-trial activity before ReCor elected to withdraw. The public record does not disclose whether the dismissal reflects a negotiated resolution, a strategic pivot, or changed commercial circumstances — for instance, shifts in the renal denervation regulatory or competitive landscape. The absence of a merits ruling means US8845629B2 remains in force and the validity questions ReCor sought to resolve remain open.
Filing to Voluntary dismissal in 978 days
978 days — nearly 2.7 years, above median for DJ patent actions in the Eastern District of California
Voluntarily dismissed: what the without-prejudice ruling means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s unilateral exit right
Under Federal Rule of Civil Procedure 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order at any time before the opposing party serves an answer or a motion for summary judgment. This mechanism requires no judicial approval and leaves the merits entirely unresolved. It is one of the cleanest procedural exits available in US federal litigation, and its use here means the court made no findings on US8845629B2’s validity or ReCor’s non-infringement.
No merits rulingWithout prejudice vs. with prejudice: the public record is silent on finality
The verdict expressly states dismissal ‘without prejudice,’ meaning ReCor is not barred from re-filing a declaratory judgment action on the same patent in future. A with-prejudice dismissal would operate as a final judgment on the merits and permanently foreclose re-filing. Here, the without-prejudice designation preserves ReCor’s optionality. However, whether ReCor intends to re-file — or whether the dismissal reflects a broader commercial resolution — is not discernible from the public court record.
Re-filing not barredReCor exits without the validity ruling it sought
ReCor initiated this action seeking certainty — likely a declaration that US8845629B2 is invalid or not infringed by its Paradise system. By voluntarily dismissing, ReCor ends the litigation without achieving that objective. The Paradise system continues to operate under the shadow of Medtronic Ardian’s patent. Whether ReCor secured any informal comfort — through licensing negotiations or other commercial arrangements — is unknown from the public record.
No declaration obtainedMedtronic’s patent survives intact — enforcement rights preserved
For Medtronic Ardian, the voluntary dismissal is a favourable procedural outcome: US8845629B2 was never adjudicated invalid or found not infringed. The patent remains in force and fully enforceable. Medtronic retains the ability to assert the patent offensively against ReCor or other competitors in the renal denervation space. The absence of a court ruling sustaining the patent’s validity, however, means it has not been judicially tested, which could weigh in any future enforcement campaign.
Patent remains enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ReCor Medical, Inc. | Company | Ultrasound renal denervation device maker — seeker of declaratory judgment on US8845629B2Search in Eureka ↗ |
| Defendant | Medtronic Ardian Luxembourg S.A.R.L. | Individual | Medtronic subsidiary holding renal denervation patent portfolio, including US8845629B2Search in Eureka ↗ |
| Plaintiff counsel | Matthew Moore | Attorney | Counsel for ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael R. Seringhaus | Attorney | Counsel for ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Roger J. Chin | Attorney | Counsel for ReCor Medical, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Latham & Watkins, LLP | Law Firm | Representing ReCor Medical, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Kandis A. Westmore | Judge | California Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) in precise terms, confirming this was a unilateral plaintiff action requiring no court order or judicial finding. The phrase ‘without prejudice’ is dispositive: no claim preclusion attaches, and the parties’ legal positions regarding US8845629B2 remain exactly as they were before filing. For Medtronic Ardian, the practical effect is a fully intact patent with no judicial record of challenge. For ReCor, the exit preserves flexibility but foregoes the certainty a declaratory judgment would have provided.
US8845629B2 — Ultrasound-based renal denervation catheter technology
US8845629B2, held by Medtronic Ardian Luxembourg S.A.R.L., covers technology in the ultrasound-based renal denervation space — specifically, the delivery of targeted energy via catheter to renal nerves to modulate sympathetic nervous system activity as a treatment for drug-resistant hypertension. The application number US12/754337 places its origin in the early wave of renal denervation patent filings, a period of intense IP activity as clinical interest in catheter-based hypertension therapies accelerated. The ‘B2’ designation indicates the patent was granted with corrected or amended claims.
In the context of the renal denervation market — where ReCor Medical’s Paradise system and Medtronic’s own Symplicity catheter system are leading commercial platforms — US8845629B2 represents a strategically significant asset. ReCor’s decision to seek a declaratory judgment signals that it assessed the patent as a credible threat to its Paradise system’s freedom to operate. For device manufacturers and investors in the catheter-based hypertension therapy space, this patent warrants careful claim-mapping, particularly given the increasing clinical evidence supporting renal denervation and regulatory momentum in the US and EU.
Should your renal denervation product be cleared against US8845629B2?
Any medical device company developing or commercialising ultrasound-based or catheter-based renal denervation systems should treat US8845629B2 as a priority FTO target. The fact that a well-resourced competitor — ReCor Medical, represented by Latham & Watkins — initiated a declaratory judgment action against this patent is a strong signal of its perceived breadth and commercial relevance. Product teams working on renal nerve ablation platforms, energy delivery catheters, or sympathetic nervous system modulation devices should commission a dedicated claim analysis before market entry or product iteration.
PatSnap Eureka’s FTO Search Agent can rapidly map the claims of US8845629B2 against your device’s technical specifications, flag design-around opportunities, and surface the full Medtronic Ardian renal denervation portfolio for comparative analysis. Eureka’s AI-assisted claim charting reduces the time and cost of manual FTO work, giving your IP and R&D teams actionable clearance intelligence ahead of regulatory submissions or commercial launch decisions.
Run a freedom-to-operate analysis on US8845629B2 to assess your product’s exposure
Run FTO in Eureka →Similar renal denervation and medical device DJ patent cases
Explore declaratory judgment patent actions involving ultrasound renal denervation and catheter-based medical device technology filed in California federal courts.
What this case signals for the renal denervation IP landscape
A withdrawn DJ action over ultrasound renal denervation technology leaves competitive patent risk unresolved — and commercially significant questions open.
Unresolved validity creates ongoing exposure for Paradise system operators
US8845629B2 was never adjudicated, meaning competitors deploying ultrasound-based renal denervation technology — including ReCor’s Paradise system — remain exposed to infringement claims. Any company in this space should assess whether their product reads on the claims of this patent before commercialising further.
Voluntary DJ dismissals often signal negotiation activity behind the scenes
When a plaintiff files a declaratory judgment action, then withdraws after nearly three years without a ruling, it typically suggests substantive engagement between the parties — whether licensing discussions, cross-licensing, or commercial settlement. Monitoring subsequent licensing filings or SEC disclosures may reveal the full picture.
ReCor v Medtronic — key questions answered
ReCor Medical voluntarily dismissed the action without prejudice on 17 September 2024, pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). No merits ruling was issued on US8845629B2. The dismissal without prejudice means ReCor is not barred from re-filing a declaratory judgment claim in the future.
The patent at issue was US8845629B2 (application number US12/754337), held by Medtronic Ardian Luxembourg S.A.R.L. It covers ultrasound-based renal denervation technology — specifically, catheter-delivered energy targeting renal nerves to modulate sympathetic nervous system activity as a treatment for drug-resistant hypertension. ReCor’s Paradise Ultrasound Renal Denervation system was the accused product.
A declaratory judgment action allows a party facing potential patent infringement liability to proactively seek a court ruling on validity or non-infringement before being sued. ReCor’s filing suggests it assessed US8845629B2 as a credible threat to its Paradise system’s commercial freedom to operate. Filing first gives the plaintiff some control over venue and timing — though the case was ultimately withdrawn before any ruling.
Yes. A dismissal without prejudice under Rule 41(a)(1)(A)(i) does not constitute a final judgment on the merits and does not trigger claim preclusion. ReCor retains the right to re-file a declaratory judgment action on US8845629B2. Whether it would do so depends on commercial circumstances, any intervening licensing arrangements, and the strategic landscape at the time — none of which are disclosed in the public record.
Medtronic Ardian’s enforcement rights under US8845629B2 are fully preserved. The patent was never found invalid or not infringed, and no estoppel arose from this proceeding. Medtronic Ardian retains the ability to assert the patent offensively against ReCor or other competitors in the renal denervation market. The patent has, however, not been judicially tested for validity, which could be a factor in any future enforcement or licensing negotiation.
PatSnap Eureka searches patents and litigation data to answer instantly.